![\"PVT](\"http:\/\/www.tomgrimshaw.com\/tomsblog\/wp-content\/uploads\/2021\/04\/PVT_Risk-300x169.png\")
<\/p>\n<\/p>\n
A potentially fatal blood-clotting disease is 30 times more common among people who have received the Covid-19 vaccines produced by Moderna and Pfizer than those given the troubled AstraZeneca jab, researchers have found.<\/p>\n
A team of scientists from the University of Oxford has found that after vaccination, Vaxzevria (formerly AstraZeneca Covid-19 vaccine) recipients were less likely to suffer portal vein thrombosis (PVT) \u2013 blood clots in the artery from the intestines to the liver.<\/p>\n
For recipients of the viral vector Vaxzevria vaccine, the incidence rate for splanchnic thrombosis \u2013 clotting in the portal and other abdominal veins \u2013 is 1.6 per million people, according to data from the EU drugs regulator the European Medicines Agency (EMA). By contrast, some 44.9 cases of PVT per million people were seen among those who had been injected with the mRNA vaccines made by Moderna and Pfizer, the Oxford research, published on Thursday, said.<\/p>\n
https:\/\/www.rt.com\/news\/521313-pvt-bloodclot-mrna-covid-vaccines\/<\/p>\n","protected":false},"excerpt":{"rendered":"
A potentially fatal blood-clotting disease is 30 times more common among people who have received the Covid-19 vaccines produced by Moderna and Pfizer than those given the troubled AstraZeneca jab, researchers have found. A team of scientists from the University of Oxford has found that after vaccination, Vaxzevria (formerly AstraZeneca Covid-19 vaccine) recipients were less … <\/p>\n